Drug-eluting stents for the treatment of coronary artery disease
KEYWORDS: patients, dess, group, des, bms, data, assessment, price, risk, assessment group, compared, ses, committee, pes, months

significant decreases in the prices of DESs); volume commitment; period commitment; combination of period and volume commitment; product rationalisation or standardisation; retrospective threshold discounts (for example, free set quantities of stents when agreed volumes have been exceeded); consignment stock (for instance, when a supplier provides an inventory to trust); and other added value inclusive arrangements (for example, the provision of additional training and related equipment). 3.6 From the sample 2007/08 data received from the NHS Purchasing and Supply Agency for NHS organisations in England for the stents included in this appraisal, the mean price of DES was £529 and the mean price of BMS was £131. The price difference between DESs compared with BMSs ranged from £203 to £615 across a number of Health Authorities in England, although it should be noted that the higher price differences tended to be seen in the older contracts which will be re- tendered in due course, in accordance with relevant contract renewal schedules. 4 Evidence and interpretation The Appraisal Committee considered evidence from a number of sources. 4.1 Clinical effectiveness DESs versus BMSs – evidence from randomised controlled trials 4.1.1 A total of 17 randomised controlled trials (RCTs) were identified that compared DESs
